Research SMA
To relieve the need and protect the health of children and their families affected by Spinal Muscular Atrophy (SMA) throughout England & Wales for the public benefit by:a. Working to improve the understanding and knowledge of Spinal Muscular Atrophy (SMA) among the public.b. Providing financial support to further advance clinical research into Spinal Muscular Atrophy (SMA).
Financial health, per its FY2026 accounts
The accounts state that the charity achieved a net income of £113,306 for the year ended 24 January 2026, resulting in total net assets of £256,798. Per the trustees' report, all income was unrestricted, and the charity maintains adequate reserves to continue in operation and meet its obligations as they fall due.
What the accounts disclose
Trustees
- George Alec Moseychair
- Charlotte Jessica Mosey
- David Charles Auckland
- Janet Elizabeth Harvey
- Matthew Atkinson
- Paul Drayton
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 24/01/2026 | £134k | £21k |
| 24/01/2025 | £136k | £175k |
| 24/01/2024 | £189k | £6k |
Common questions
Is Research SMA financially healthy?
Per its FY2026 accounts: The accounts state that the charity achieved a net income of £113,306 for the year ended 24 January 2026, resulting in total net assets of £256,798. Per the trustees' report, all income was unrestricted, and the charity maintains adequate reserves to continue in operation and meet its obligations as they fall due. Its FY2026 accounts were independently examined.
Who funds Research SMA?
Funders whose own accounts filings name Research SMA as a grant recipient include The Bridgepoint Group Foundation.
Known funders
| Funder | Year | Amount | Purpose (as stated by the funder) |
|---|---|---|---|
| The Bridgepoint Group Foundation | FY2023 | £32k |